linjc16/ctgov huggingface dataset:
Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
This is a phase Ⅱ trial of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.

Detailed Description
-----------------
The main purpose of this study is to evaluate the efficacy and safety of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.

Official Title
-----------------
Phase Ⅱ Trial of Fixed Dose Rate Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Capecitabine in Patients With Locally Advanced Pancreatic Cancer

Conditions
-----------------
Pancreatic Cancer

Intervention / Treatment
-----------------
* Drug: gemcitabine, cisplatin, capecitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unresectable locally advanced pancreatic cancer no distant metastasis histologically confirmed adenocarcinoma of pancreas 18-75 of age ECOG performance status 0-2 normal marrow function : WBC at least 3,000/mm3 OR Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 normal liver function : --Bilirubin no greater than 2.0 mg/dL AST less than 3 times upper limit of normal (ULN) normal renal function : --Creatinine no greater than 1.5 times ULN signed informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to progression |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety | number of patients who experienced grade 3-4 toxicity by NCI-CTCAE | 12 months | 
| 1 year survival rate |  | 1 year | 
| response rate | response rate by RECIST criteria | 1 year | 
| overall survival |  | 1 year | 
| clinical benefit rate | CR+PR+SD by RECIST criteria | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
locally advanced
The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）

Study Overview
=================
Brief Summary
-----------------
Collect the details about hepatic dysfunctional patients induced by various etiology who have a usage of Glycyrrhizic Acid, then arrange and analyse the data to evaluate the clinical curative effect of glycyrrhizic acid.

Detailed Description
-----------------
This experiment will screen and collect qualified cases from medical records in Shuguang Hospital.to collect the patients with liver injury in clinic, including (1) conforms to ALT>1.5 times the normal value or >70 IU/L, age 18 to 70 years of age, sex is not limited; (2) patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ; (3) except for tumor patients. The index of liver function such as ALT, AST, Alb, et al are detected respectively before and after preventive treatment of the glycyrrhizic acid for liver injury ,and through the synthesizing of the single sample difference t test and clinical practice to analyze the clinical efficacy of glycyrrhizin intervention treatment of hepatic injury

Official Title
-----------------
The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）

Conditions
-----------------
Liver Damage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: conforms to ALT>1.5 times the normal value or >70IU/L, age 18 to 70 years of age, sex is not limited; patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ; Exclusion Criteria: patients with tumor; pregnant or lactating women, and pregnancy may not take effective contraceptive measures; complicated with serious heart, lung, gallbladder, kidney, endocrine, hematopoietic system and mental disease; the researchers think that should not be selected for this test.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical indexes measured before and after the interference | to measure biochemical indexes such as ALT, AST, ALB, TBiL, et al before and after the interference with Glycyrrhizic Acid | 1-4 weeks |
Treatment With Duloxetine for OCD Patients

Study Overview
=================
Brief Summary
-----------------
Testing the efficacy of the SNRI medication Duloxetine for treating OCD patients who did not respond to SSRI

Conditions
-----------------
OCD

Intervention / Treatment
-----------------
* Drug: Duloxetine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: OCD as main diagnosis according to DSM-IV Age 18 to 65 Men and women YBOCS score is 18 or more, or 12 or more in case of only obsessions Exclusion Criteria: Patients treated with Duloxetine, currently or in the past Patients having comorbid schizophrenia or psychotic disorder or bipolar disorder Patients with substance abuse disorder in the last 6 months Patients who were suicidal or did serious suicide attempt in the last year Pregnant or lactating women, or woman of childbearing potential, which is not using adequate contraception Patients with neurologic disturbance or disorder Patients with serious or imbalanced medical condition Patients with allergic response to SSRI or duloxetine Patients who started new treatment (CBT or pharmacology) in less than 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Duloxetine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Mid-Term Natural Course Postoperative of Crowe Type III-IV Hip Dysplasia

Study Overview
=================
Brief Summary
-----------------
Comparison of preoperative and postoperative mid-term course of patients with Crowe Type 3 and Type 4 hip dysplasia.

Detailed Description
-----------------
Crowe type 3 and type 4 patients who underwent shortened hip replacement surgery will be followed up for 2 years. Patients will be called for routine outpatient controls at the 2nd week, 6th week, 3rd month, 6th month, 12th month, 24th month. Patients will be referred to the physical therapy specialist for abduction strengthening and pelvis tilt corrective exercises starting from the 6th week. Scoliosis and orthoroentgenography x-rays will be taken at the last control of the patients. HHS, WOMAC hip score and SF-12 score will be obtained from the patients. Scores, lower extremity and spine angles will be evaluated after the last examinations performed at 12 and 24 months.

Official Title
-----------------
Mid-Term Natural Course of Lower Extremity and Spine After Total Hip Arthroplasty in Patients With Crowe Type III-IV Hip Dysplasia

Conditions
-----------------
Hip Arthropathy, Hip Dysplasia

Intervention / Treatment
-----------------
* Procedure: Shortened hip arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Crowe type 3 and 4 patients over 18 years of age who had shortened hip replacement surgery Exclusion Criteria: Crowe type 1 or 2 patients over 18 years of age who had shortened hip replacement surgery Patients who have previously operated on the contralateral hip Patients who underwent shortened hip replacement for a reason other than developmental dysplasia of the hip

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Patients over the age of 18 who underwent Crowe Type 3 and Type 4 shortened hip prosthesis
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Crowe type 3 and 4 patients undergoing shortened hip replacement<br>Clinical and radiological results of Crowe type 3 and 4 patients who underwent shortened hip prosthesis at 12 and 24 months | Procedure: Shortened hip arthroplasty<br>* Crowe type 3 and 4 patients who underwent shortened hip prosthesis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | The WOMAC score range, which indicates the clinical satisfaction of the patients, is between 0-100. | The degree of improvement in Vomac score will be evaluated by looking at preoperative and postoperative 12th month Vomac scores.( 0-12th month ) |
Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

Study Overview
=================
Brief Summary
-----------------
To determine if celecoxib 200 mg once daily is as effective as diclofenac 50 mg three times daily in the treatment of pain symptoms associated with osteoarthritis of the hip

Official Title
-----------------
Clinical Protocol For A Multicentre, Double-Blind, Randomised, Parallel Group Study To Compare The Efficacy and Tolerability Of Celecoxib Vs. Diclofenac In The Treatment Of Subjects With Osteoarthritis Of The Hip Requiring Joint Replacement Therapy

Conditions
-----------------
Osteoarthritis, Hip

Intervention / Treatment
-----------------
* Drug: Celecoxib
* Drug: Diclofenac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with osteoarthritis of hip and requiring joint replacement Eligible for chronic therapy with an NSAID Exclusion Criteria: Hip surgery anticipated within 8 calendar weeks after first visit Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration (within 60 days of first visit)

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Celecoxib|nan|
|Drug: Diclofenac|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in patient assessment of arthritis pain on walking VAS (Visual Analog Scale) as measured on a 0-100 mm scale at week 6 compared to baseline |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in patient assessment of arthritis pain on walking VAS (Visual Analog Scale) as measured on a 0-100 mm scale at week 12 compared to baseline. |  |  | 
| Change in patients global assessment of arthritis between treatment groups. |  |  |
Far Infrared Irradiation for Stroke Rehabilitation

Study Overview
=================
Brief Summary
-----------------
A stroke is a sudden loss of brain function. It is caused by the interruption of flow of blood to the brain (ischemic stroke) or the rupture of blood vessels in the brain (hemorrhagic stroke). This study will investigate the use of far infrared radiation for stroke rehabilitation.

Detailed Description
-----------------
A stroke is a sudden loss of brain function. The interruption of blood flow or the rupture of blood vessels causes brain cells (neurons) in the affected area to die. The effects of a stroke depend on where the brain was injured, as well as how much damage occurred. A stroke can impact any number of areas including your ability to move, see, remember, speak, reason and read and write. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people with stroke.

Official Title
-----------------
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Stroke Rehabilitation

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Radiation: Far Infrared Radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People with Stroke Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Radiation: Far Infrared Radiation (5μm to 20μm wavelength) | Radiation: Far Infrared Radiation<br>* Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Management and Cure of Stroke |  | 2 Years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rehabilitation of the following: ability to move, see, remember, speak, reason and read and write. |  | 2 Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Apoplexy, Cerebral Stroke, Cerebrovascular Accident, Cerebrovascular Accident, Acute, Cerebrovascular Apoplexy, Cerebrovascular Stroke
Merck IISP Stewardship Grant for Antibiotic Best Practices

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to pilot the use of best practices alerts to enhance an antimicrobial stewardship program using the electronic medical record, EPIC.

Detailed Description
-----------------
The purpose of this study is to pilot the use of best practices to enhance an antimicrobial stewardship program using the electronic medical record, EPIC. Screening information technology tools via SETNET/Safety SUrveyor(Premier) and the electronic anti-infective order form would allow for sufficient medical record review to create best practices alerts for the purpose of appropriate de-escalation of anti-invectives.

Official Title
-----------------
Implementation of Antimicrobial Stewardship and Decision Support Into the EPIC Electronic Medical Record

Conditions
-----------------
Antibiotic Resistant Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physicians with prescribing privileges at the UWHC Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All prescribing MDs at UWHC<br>Observational for accept, reject, or accept with modification of Best Practice Alers | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of best practice alerts(BPA) that were completely accepted, partially accepted, or rejected within 72 hours of issuing the BPA | after issuing the BPA for deescalation, the responding healthcare provider will respond in one of the manners above | One Year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number and type of antiinfectives that were administered before and after(11days) the best practice alert is issued. | The antiinfective use before and after the BPA will be analyzed in detail. The number of antibiotics, percentage decrease(or less likely increase) in antiinfectives in the 3 days before BPA , and 11 days after the BPA will be analyzed. A cost analysis will be performed. Patient outcomes will not be assessed. | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
deescalation, best practice alert, antimicrobial stewardship
Reduction of Excessive Calories From Beverages in Children

Study Overview
=================
Brief Summary
-----------------
Objective: to test the hypothesis that an intervention comprised of targeted physician and print messages can influence parents to reduce the amount of sugar-sweetened beverages (SSB) and fruit juice they give to their children 1 - 12 years of age.

Detailed Description
-----------------
The study will be conducted through a practice-based research network of community pediatric practices. Participating sites will be randomized to the intervention or control condition (usual care) using a pre-specified randomization scheme derived using computer generated random numbers. The intervention sites will participate in a 30-minute training for using the Milk. Water. Period intervention (brochures, posters, key talking points and phone messages) in their office. The goal is for them to discuss beverage consumption and encourage Milk. Water. Period for all children 12 months to 12 years old (not yet reached their 13th birthday) at their checkup visit. The primary care provider (PCP) will use the talking points to facilitate the discussion about drink milk and water only and will give a brochure to each family. Assessments will be by telephone interview of the parent 2 to 4 weeks after a check-up visit for the index child.

Official Title
-----------------
Randomized Controlled Trial to Reduce Calorie Intake From Sugar-sweetened Beverages by Children 1 - 12 Years of Age

Conditions
-----------------
Unhealthy Diet

Intervention / Treatment
-----------------
* Behavioral: Physician communication


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parent of child age 12 months to 12 years attending for a check-up visit during the study period Exclusion Criteria: Cannot speak English No phone access Already completed the survey for another child.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Physician communication<br>The Milk. Water. Period intervention comprises brochures, posters, and key talking points for use by primary pediatricians to use in discussion with the parent about the child's beverages consumption. | Behavioral: Physician communication<br> <br> |
| No Intervention: Usual care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Excessive calories from beverages | percent of children consuming >200 calories/day from soda, SSBs, and fruit juice beverages | 2-4 weeks after check-up visit |
Brain Oxygenation During Cardiopulmonary Resuscitation

Study Overview
=================
Brief Summary
-----------------
The study is aimed to assess (a) the incidence of hyperoxia at the point of return of spontaneous circulation (ROSC) and (b) the role of arterial blood oxygen partial pressure to brain oxygenation during out-of-hospital cardiac arrest. 80 adult patients will be recruited in a physician staffed helicopter emergency medical services. Brain regional oxygen saturation and invasive blood pressure are monitored until hospital admission and arterial blood gases are analyzed immediately when the unit arrives to the patient and again at the time of ROSC.

Official Title
-----------------
Brain Oxygenation During Cardiopulmonary Resuscitation - Observational Pilot Study

Conditions
-----------------
Cardiac Arrest, Out-Of-Hospital

Intervention / Treatment
-----------------
* Other: Standard cardiopulmonary resuscitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: out-of-hospital cardiac arrest of presumed cardiac origin resuscitation will be continued at least 5 minutes (if return of spontaneous circulation not achieved earlier) after arrival of physician team Exclusion Criteria: do-not-attempt-resuscitation (DNAR) order or withdrawal of treatment by prehospital critical care physician return of spontaneous circulation achieved before physician-led critical team arrives external cause for cardiac arrest (e.g. trauma, suffocation) workload too high or environment too dangerous to perform study procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Standard cardiopulmonary resuscitation|Standard Advanced Life Support based on guidelines 2015, including mechanical chest compression device|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial oxygen partial pressure | Arterial oxygen partial pressure at the time of return of spontaneous circulation (ROSC) | 5-60 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Forehead regional oxygen saturation during resuscitation | Oxygen saturation measured using near-infrared spectroscopy | 0-60 minutes |